Global Industry Analysts has released a new research report titled ‘Nanobiotechnology: A Global Strategic Business Report.’
According to the report, the global nanobiotechnology market is expected to achieve a value of $6 billion in 2017, and will be driven primarily by technology developments, increased participation by private venture capitalists, and government funding in research and development especially in developing nations.
The report provides a comprehensive review of growth factors, barriers, market trends, merger and acquisition activities, and other corporate strategies and developments in the global nanobiotechnology market. It includes forecast data pertaining to product segments: nanodevices/tools and nanomaterials such as fullerenes, nanotubes, nanostructured materials and membranes, nanocomposites and solid inorganic nanoparticles.
Application segments of the global nanobiotechnology market covered in the report include medical research, medical devices, pharmaceuticals, and others. Geographic markets discussed in the report include the United States, Europe, Japan, and Rest of World. The report predicts that nanooncology will witness a strong growth, which will be driven by the discovery of new cancer biomarkers, advancements in the utilization of quantum dots and gold nanoparticles in cancer diagnosis, and nanobiosensor development that leads to the discovery of highly sensitive protein biomarkers.
Nanobiotechnology’s largest users are and will be pharmaceutical and biotechnology industries. Extensive research work in nanobiotechnology leads to the development of advanced nanofabricated devices and systems for treatment of numerous acute diseases, while microfabrication shows promise in designing miniature biological systems.
The US is the largest nanobiotechnology market in the world. Although the US, European Union and Japan have made huge investments in all nanotechnology research and development, strong growth is expected from nations in the Asia-Pacific region. The report predicts that Middle East, Latin America, and Asia-Pacific are expected to grow at 25.3% CAGR during the reporting period.
Companies mentioned in the report include Zyvex Instruments, SkyePharma Pharmaceuticals, Dendritic Nanotechnologies, Starpharma, Sigma Aldrich, Nanophase Technologies, Gilead Sciences, Arrowhead Research, Aduro BioTech, Calando Pharmaceuticals, Biosante Phosphate Pharmaceuticals and Asklepios BioPharmaceutical.
Source: http://www.strategyr.com